Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.07 | 1.36 |
NAV | ₹19.26 | ₹200.81 |
Fund Started | 31 Oct 2022 | 07 May 2007 |
Fund Size | ₹1425.91 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1% if redeemed within 180 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -2.92% | 6.10% |
3 Year | - | 25.05% |
5 Year | - | 28.68% |
1 Year
3 Year
5 Year
Equity | 98.61% | 93.60% |
Cash | 1.28% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Godfrey Phillips India Ltd. | 4.63% |
Motilal Oswal Financial Services Ltd. | 3.15% |
JK Cement Ltd. | 3.07% |
Cummins India Ltd. | 2.65% |
Coforge Ltd. | 2.64% |
Avalon Technologies Ltd. | 2.54% |
Jubilant FoodWorks Ltd. | 2.45% |
Waaree Energies Ltd. | 2.45% |
Marico Ltd. | 2.41% |
Tube Investments Of India Ltd. | 2.39% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Satish Ramanathan | Chirag Setalvad |
Start Date | 01 Oct 2024 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. There is no assurance that the investment objective of the Scheme will be realized. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 31 Oct 2022 | 07 May 2007 |
Description
Launch Date